statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gagnants
L'action Acrivon Therapeutics (NASDAQ:ACRV) a grimp mardi de 73,43% 10,25 dollars lors de la session ordinaire.
L'action BioSig Technologies (NASDAQ:BSGM) a augment de 24,20% 1,54...

12 titres de soins de sant  en mouvement lors de la session du 09/04/2024

Acrivon Therapeutics has entered into a securities purchase agreement to issue and sell 8.235 million shares of its common stock at a price of $8.50 per share, as well as pre-funded warrants to...

Acrivon Therapeutics Stock Is Soaring Tuesday: What's Going On?

Gagnants
Le titre Acrivon Therapeutics (NASDAQ:ACRV) a mont mardi de 75,12% 10,35 dollars lors de la session pre-market.
Le titre Biophytis (NASDAQ:BPTS) a augment de 40,48% 0,45 dollars.
Le...

12 titres de soins de sant  en mouvement lors de la pr -ouverture le 09/04/2024

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report)s stock had its "outperform" rating restated by stock analysts at BMO Capital Markets in a research report issued on Monday, Benzinga...

BMO Capital Markets Reiterates Outperform Rating for Acrivon Therapeutics (NASDAQ:ACRV)

Silvan Tuerkcan, an analyst from JMP Securities, maintained the Buy rating on Acrivon Therapeutics, Inc. (ACRV Research Report). The associated p...

Buy Rating on Acrivon Therapeutics: Anticipated Clinical Validation and Strong Financial Position

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 484,000 shares, a growth...

Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Increases By 22.7%

HC Wainwright reissued their buy rating on shares of Acrivon Therapeutics (NASDAQ:ACRV - Free Report) in a research report report published on Thursday, Benzinga reports. HC Wainwright currently has...

Acrivon Therapeutics (NASDAQ:ACRV) Receives "Buy" Rating from HC Wainwright

Comparing ACRV's Performance to Analyst Projections and Unveiling Key FinancialsRelated Stocks: ACRV...

Acrivon Therapeutics Inc (ACRV) Reports Increased Annual Loss: A Detailed Look Against Analyst ...

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report)s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a research report issued on Thursday, Benzinga...

Acrivon Therapeutics (NASDAQ:ACRV) Rating Reiterated by HC Wainwright

Acrivon Therapeutics, Inc. (NASDAQ:ACRV  Free Report)  Analysts at HC Wainwright issued their Q1 2024 EPS estimates for shares of Acrivon Therapeutics in a research report issued on...

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Expected to Earn Q1 2024 Earnings of ($0.88) Per Share

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.

Volume	22,441.00
52-Wk High	$14.30
52-Wk Low	$3.19

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.84	--	--	N/A
Q4'23	-$0.72	-$0.86	-18.89%	MISSED
Q3'23	-$0.71	-$0.66	6.82%	BEAT
Q2'23	-$0.65	-$0.63	2.78%	BEAT
Q1'23	-$0.65	-$0.58	10.84%	BEAT

ACRV ACRIVON THERAPEUTICS INC

About

Feed

News

Earnings

Fundamentals